Parathyroid hormone is a Recombinant Peptide owned by Takeda Pharmaceutical, and is involved in 27 clinical trials, of which 24 were completed, and 3 are ongoing.

Parathyroid hormone (SHP-634/Natpar) acts on bone generating cells called osteoblasts to stimulate new bone formation. Osteoblasts are mononucleate cells that are responsible for bone formation. Osteoblasts are sophisticated fibroblasts that express all genes that fibroblasts express, with the addition of the genes for bone sialoprotein and osteocalcin. SHP-634 is identical in structure to the 84 amino acid single-chain polypeptide human parathyroid hormone and mimics the action of natural parathyroid hormone, hence it has the potential to be the hormone therapy for hypoparathyroidism and return the body to a physiological or “eucalcemic” state. SHP-634 treatment in hypoparathyroidism significantly reduces supplemental calcium and 1, 25-dihydroxyvitamin D requirements while maintaining serum calcium levels.

The revenue for Parathyroid hormone is expected to reach a total of $2.6bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Parathyroid hormone NPV Report.

Parathyroid hormone was originated by Allelix Biopharmaceuticals and is currently owned by Takeda Pharmaceutical.

Parathyroid hormone Overview

Parathyroid hormone (Preotact / Preotakt / Natpara / SHP-634 / TAK-834 / Natpar) is produced in Escherichia coli by recombinant DNA technology. It is formulated as powder for solution for injection for subcutaneous route of administration. It is indicated for the treatment of osteoporosis (a disease that makes bones fragile) in postmenopausal women who are at high risk of fractures. Parathyroid Hormone (SHP-634/Natpar) indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism.

It was under development for hypothyroidism in Japan. It was also under development for the treatment of postmenopausal women with osteoporosis in the U.S.

Takeda Pharmaceutical Overview

Takeda Pharmaceutical (Takeda) is a research-based pharmaceutical company which focuses on the discovery, development, manufacturing, marketing, commercialization, import and export of pharmaceutical drugs. The company offers products in the areas of rare diseases, gastrointestinal, oncology, neuroscience, vaccines, and plasma-derived therapies. Takeda has facilities in Japan, Argentina, Brazil, Mexico, the US, Denmark, Norway, Europe, Poland, Russia, Spain, Switzerland, China and India, Canada among others. It markets products directly and through a network of wholesale distributors, retail chains and other purchasing groups worldwide. Takeda has partnership with academic institutions, small biotech, and large pharmaceutical companies. It has presence in the Americas, Europe, and Asia, among others. Takeda is headquartered in Tokyo, Japan.

The company reported revenues of (Yen) JPY3,569,006 million for the fiscal year ended March 2022 (FY2022), an increase of 11.6% over FY2021. In FY2022, the company’s operating margin was 12.5%, compared to an operating margin of 18.8% in FY2021. In FY2022, the company recorded a net margin of 6.4%, compared to a net margin of 11.8% in FY2021. The company reported revenues of JPY1,002,307 million for the second quarter ended September 2022, an increase of 3.1% over the previous quarter.

Quick View – Parathyroid hormone

Report Segments
  • Innovator (NME)
Drug Name
  • Parathyroid hormone
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Hormonal Disorders
  • Musculoskeletal Disorders
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.